Teijin Limited

Meiji Seika Kaisha, Ltd.

Veritas in Silico Inc.

Takashi Kamimura

Atsushi Imaizumi

Kenichi Masuda

Masahiro Okada

Takashi Sugiyama

Yoji Suzuki

Yorimasa Suwa

Tatsuki Shiota

Eiko Ohtsuka

Keizo Inoue

Tomohiro Ohta

Naoki Tsuchiya

Naoki Hase

Toru Sasaki

Ichiro Kudo

Takashi Kawamura

Takumi Takeyasu

Yasuhiro Takano

Ling Jin

Osami Takenouchi

Masaichi Hasegawa

Shingo Nakamura

Masaki Sudoh

Yumiko Muroga

Hideki Horiuchi

Tomonori Yokoyama

Masato Tani

Akinobu Nakanishi

Yohichi Matsumoto

Tetsuya Suga

Katsushi Takahashi

Akiko Takeuchi

Kunihito Watanabe

Hideo Inoue

Amiu Shino

Yasuhiro Gyobu

Chieko Moriyama

Toshiaki Harada

Fuminori Miyagi

Akihiro Imura

A method for screening for a compound capable of modulating gene expression by calculating an existence probability of a local secondary structure that may exist in a target RNA sequence; selecting a local secondary structure with the desired existence probability; preparing a screening probe corresponding to the selected local secondary structure; and screening for the compound using the probe.

Method for screening compound for controlling RNA function

A medicine containing, as an active ingredient, a cyclic amine derivative represented by the following formula (I), a pharmaceutically acceptable acid addition salt thereof or a pharmaceutically acceptable Cto Calkyl addition salt thereof. The medicine has an action for treating or preventing diseases in which CCR3 participates, such as asthma and allergic rhinitis.

Cyclic amine CCR3 antagonist

This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 &#x3b1; and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain, as the active ingredient, cyclic amine derivatives represented by the following formula (I), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C-Calkyl addition salts thereof.

Remedies or prophylactics for diseases in association with chemokines

SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities

The present invention provides an elastase inhibitory polypeptide comprising a C-terminal half of a human secretory leukocyte protease inhibitor (SLPI) and having an elastase inhibitory activity wherein inhibitory activity of a trypsin-like serine protease does not exceed 1/10 of elastase inhibitory activity, and polypeptides having the above-mentioned biological activity wherein one or more than one amino acid is added, one or more than one amino acid is deleted and/or one or more than one amino acid is replaced. The present invention also provides a process for the production of the above-mentioned protein or other protein via a corresponding fused protein.

Elastase inhibitory polypeptide and process for production thereof by

Benzene derivatives

Calcitonin derivatives wherein at least one of the first cysteine residue and the seventh cysteine residue is S-sulfonated; processes for the production of the calcitonin derivatives comprising the steps of reacting a calcitonin with a sulfite anion or both a sulfite anion and an oxidizing agent to form the S-sulfonated derivative, and recovering the sulfonated calcitonin derivative; a pharmaceutical composition comprising the S-sulfonated calcitonin derivative; and a method of treating a patient having a disease wherein a decrease of a serum calcium level is desired, by administering the S-sulfonated calcitonin derivative to the patient.

S-sulfonated calcitonin derivatives

Protein having an inflammatory phospholipase A.sub.2 inhibitory activity

Pyridopyrimidine nucleotide derivatives expressed by formula (I), which are fluorescent and capable of forming base pairing with guanine or adenine, and oligo- or polynucleotide which have at least one of these derivatives in their molecules or at their molecular terminals: ##STR1## wherein X.sub.1 and X.sub.1 respectively represent ##STR2## (in which n indicates an integer of 0, 1, 2, or 3; however, in no case X.sub.1 and Y.sub.1 both indicate n=O); Z.sub.1 indicates a hydrogen atom or ##STR3## (in which n indicates an integer of 1, 2, or 3); W.sub.1 indicates a hydrogen atom or a hydroxyl group. As for R.sub.1 and R.sub.2, in case where R.sub.1 is an amino group or halogen, R.sub.2 indicates a single bond between the carbon atom at the 7-position and the nitrogen atom at the 8-position, and in case where R.sub.2 is a hydrogen atom or an lower alkyl group, R.sub.1 indicates a carbonyl bond ##STR4## formed with the carbon atom at the 7-position.

Pyridopyrimidine nucleotide compounds

Protein having a phospholipase A.sub.2 inhibitory activity which has the nature to be induced from cells upon administration of glucocorticoid and has a phospholipase A.sub.2 inhibitory activity.

Protein having phospholipase A2 inhibitory activity

Growing community of inventors

Tokyo, Japan

Takashi Kamimura